Theratechnologies Stock Today
| THTX Stock | USD 1.21 0.01 0.82% |
Performance0 of 100
| Odds Of DistressOver 81
|
Theratechnologies is trading at 1.21 as of the 21st of November 2024; that is 0.82% down since the beginning of the trading day. The stock's open price was 1.22. Theratechnologies has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Theratechnologies are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 22nd of October 2024 and ending today, the 21st of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 4th of January 2016 | Category Healthcare | Classification Health Care |
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company was incorporated in 1993 and is headquartered in Montreal, Canada. The company has 45.98 M outstanding shares of which 43.03 K shares are at this time shorted by private and institutional investors with about 0.95 trading days to cover. More on Theratechnologies
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Theratechnologies Stock Highlights
| CEO President | Paul Lvesque | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsTheratechnologies can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Theratechnologies' financial leverage. It provides some insight into what part of Theratechnologies' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Theratechnologies (THTX) is traded on NASDAQ Exchange in USA. It is located in 2015 Peel Street, Montreal, QC, Canada, H3A 1T8 and employs 103 people. Theratechnologies is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 56.1 M. Theratechnologies conducts business under Biotechnology sector and is part of Health Care industry. The entity has 45.98 M outstanding shares of which 43.03 K shares are at this time shorted by private and institutional investors with about 0.95 trading days to cover.
Theratechnologies currently holds about 36.46 M in cash with (5.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.38.
Check Theratechnologies Probability Of Bankruptcy
Ownership AllocationTheratechnologies shows a total of 45.98 Million outstanding shares. Over half of Theratechnologies' outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Theratechnologies Ownership Details
Theratechnologies Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Bare Financial Services Inc | 2024-09-30 | 26.8 K | |
| Beacon Pointe Advisors, Llc | 2024-06-30 | 26.5 K | |
| Geode Capital Management, Llc | 2024-06-30 | 25.7 K | |
| Bank Of Montreal | 2024-06-30 | 18.3 K | |
| Bmo Capital Markets Corp. | 2024-06-30 | 18.3 K | |
| Ubs Group Ag | 2024-06-30 | 17.5 K | |
| Kohmann Bosshard Financial Services, Llc | 2024-09-30 | 15.4 K | |
| Greatmark Investment Partners Inc | 2024-09-30 | 14.9 K | |
| Modern Wealth Management Llc | 2024-09-30 | 11 K | |
| Nantahala Capital Management, Llc | 2024-06-30 | 5.4 M | |
| Soleus Capital Management, L.p. | 2024-06-30 | 4.8 M |
Theratechnologies Historical Income Statement
Theratechnologies Stock Against Markets
Theratechnologies Corporate Management
| LLB BA | VP Affairs | Profile | |
| H MSc | Vice Resources | Profile | |
| LLB LLM | General Secretary | Profile | |
| Elif McDonald | Director Relations | Profile | |
| Christian Marsolais | Senior Officer | Profile |
Additional Tools for Theratechnologies Stock Analysis
When running Theratechnologies' price analysis, check to measure Theratechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theratechnologies is operating at the current time. Most of Theratechnologies' value examination focuses on studying past and present price action to predict the probability of Theratechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theratechnologies' price. Additionally, you may evaluate how the addition of Theratechnologies to your portfolios can decrease your overall portfolio volatility.